Imugene Ltd doses first patients of VAXINIA MAST combination trial

Imugene Ltd (ASX:IMU, OTC:IUGNF) welcomes the news that the first patients have been dosed in its Phase 1 MAST (metastatic advanced solid tumours) study...

Related Keywords

Australia ,United States ,Leslie Chong ,Imugene Ltd ,Dose Escalation Safety ,Tolerability Study ,Administered Intratumorally ,Adult Patients ,Advanced Solid Tumours ,